{"id":32732,"date":"2025-04-30T11:48:25","date_gmt":"2025-04-30T03:48:25","guid":{"rendered":"https:\/\/flcube.com\/?p=32732"},"modified":"2025-04-30T11:48:26","modified_gmt":"2025-04-30T03:48:26","slug":"fosun-pharmas-henlius-strikes-deal-with-sandoz-for-global-rights-to-hlx13-biosimilar","status":"publish","type":"post","link":"https:\/\/flcube.com\/?p=32732","title":{"rendered":"Fosun Pharma&#8217;s Henlius Strikes Deal with Sandoz for Global Rights to HLX13 Biosimilar"},"content":{"rendered":"\n<p>China-based Shanghai Fosun Pharmaceutical (Group) Co., Ltd (<a href=\"https:\/\/www.google.com\/finance\/quote\/600196:SHA\">SHA: 600196<\/a>, <a href=\"https:\/\/www.google.com\/finance\/quote\/2196:HKG\">HKG: 2196<\/a>) announced that its subsidiary Shanghai Henlius Biotech Inc. (<a href=\"https:\/\/www.google.com\/finance\/quote\/2696:HKG\">HKG: 2696<\/a>) has entered into a licensing agreement with Sandoz (<a href=\"https:\/\/www.google.com\/finance\/quote\/SDZ:SWX\">SWX: SDZ<\/a>). The deal grants the Swiss pharmaceutical company development, manufacturing, and commercialization rights for HLX13\u2014a biosimilar of Bristol-Myers Squibb (BMS, <a href=\"https:\/\/www.google.com\/finance\/quote\/BMY:NYSE\">NYSE: BMY<\/a>)&#8217;s Yervoy (ipilimumab)\u2014in Australia, Canada, Europe, Japan, and the US.<\/p>\n\n\n\n<p><strong>HLX13 Development and Indications<\/strong><br>HLX13 is a cytotoxic T-lymphocyte-associated protein 4 (CTLA-4) monoclonal antibody (mAb) currently in Phase I clinical trials in China. It targets multiple oncology indications, including liver cancer, melanoma, advanced renal cell carcinoma, and metastatic colorectal cancer with high microsatellite instability (MSI-H) or mismatch repair deficiency (dMMR).<\/p>\n\n\n\n<p><strong>Financial Terms of the Agreement<\/strong><br>Under the agreement, Sandoz will pay Henlius an upfront payment of USD 31 million. Additional payments of up to USD 160 million are tied to development milestones, and up to USD 110 million are contingent on sales milestones, based on the drug&#8217;s net sales performance.<a href=\"https:\/\/flcube.com\/\">-Fineline Info &amp; Tech<\/a><\/p>\n\n\n\n<div data-wp-interactive=\"core\/file\" class=\"wp-block-file\"><object data-wp-bind--hidden=\"!state.hasPdfPreview\" hidden class=\"wp-block-file__embed\" data=\"https:\/\/flcube.com\/wp-content\/uploads\/2025\/04\/600196_20250430_KLM8.pdf\" type=\"application\/pdf\" style=\"width:100%;height:600px\" aria-label=\"Embed of 600196_20250430_KLM8.\"><\/object><a id=\"wp-block-file--media-44920a1d-11e7-42d9-89db-6cb7ed27bb36\" href=\"https:\/\/flcube.com\/wp-content\/uploads\/2025\/04\/600196_20250430_KLM8.pdf\">600196_20250430_KLM8<\/a><a href=\"https:\/\/flcube.com\/wp-content\/uploads\/2025\/04\/600196_20250430_KLM8.pdf\" class=\"wp-block-file__button wp-element-button\" download aria-describedby=\"wp-block-file--media-44920a1d-11e7-42d9-89db-6cb7ed27bb36\">Download<\/a><\/div>\n","protected":false},"excerpt":{"rendered":"<p>China-based Shanghai Fosun Pharmaceutical (Group) Co., Ltd (SHA: 600196, HKG: 2196) announced that its subsidiary&#8230;<\/p>\n","protected":false},"author":1,"featured_media":32736,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"googlesitekit_rrm_CAownpewDA:productID":"","_jetpack_memberships_contains_paid_content":false,"footnotes":"","jetpack_publicize_message":"","jetpack_publicize_feature_enabled":true,"jetpack_social_post_already_shared":true,"jetpack_social_options":{"image_generator_settings":{"template":"highway","default_image_id":0,"font":"","enabled":false},"version":2}},"categories":[7,10],"tags":[429,428,16,159,270,893,862,849,747,892,886],"class_list":["post-32732","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-company","category-deals","tag-bms","tag-bristol-myers-squibb","tag-cancer","tag-fosun-pharmaceutical","tag-henlius-biotech","tag-hkg-2196","tag-hkg-2696","tag-nyse-bmy","tag-sandoz","tag-sha-600196","tag-swx-sdz"],"yoast_head":"<!-- This site is optimized with the Yoast SEO Premium plugin v23.6 (Yoast SEO v27.5) - https:\/\/yoast.com\/product\/yoast-seo-premium-wordpress\/ -->\n<title>Fosun Pharma&#039;s Henlius Strikes Deal with Sandoz for Global Rights to HLX13 Biosimilar - Insight, China&#039;s Pharmaceutical Industry<\/title>\n<meta name=\"description\" content=\"China-based Shanghai Fosun Pharmaceutical (Group) Co., Ltd (SHA: 600196, HKG: 2196) announced that its subsidiary Shanghai Henlius Biotech Inc. (HKG: 2696) has entered into a licensing agreement with Sandoz (SWX: SDZ). The deal grants the Swiss pharmaceutical company development, manufacturing, and commercialization rights for HLX13\u2014a biosimilar of Bristol-Myers Squibb (BMS, NYSE: BMY)&#039;s Yervoy (ipilimumab)\u2014in Australia, Canada, Europe, Japan, and the US.\" \/>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/flcube.com\/?p=32732\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Fosun Pharma&#039;s Henlius Strikes Deal with Sandoz for Global Rights to HLX13 Biosimilar\" \/>\n<meta property=\"og:description\" content=\"China-based Shanghai Fosun Pharmaceutical (Group) Co., Ltd (SHA: 600196, HKG: 2196) announced that its subsidiary Shanghai Henlius Biotech Inc. (HKG: 2696) has entered into a licensing agreement with Sandoz (SWX: SDZ). The deal grants the Swiss pharmaceutical company development, manufacturing, and commercialization rights for HLX13\u2014a biosimilar of Bristol-Myers Squibb (BMS, NYSE: BMY)&#039;s Yervoy (ipilimumab)\u2014in Australia, Canada, Europe, Japan, and the US.\" \/>\n<meta property=\"og:url\" content=\"https:\/\/flcube.com\/?p=32732\" \/>\n<meta property=\"og:site_name\" content=\"Insight, China&#039;s Pharmaceutical Industry\" \/>\n<meta property=\"article:publisher\" content=\"https:\/\/www.facebook.com\/profile.php?id=61566606313834\" \/>\n<meta property=\"article:published_time\" content=\"2025-04-30T03:48:25+00:00\" \/>\n<meta property=\"article:modified_time\" content=\"2025-04-30T03:48:26+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/flcube.com\/wp-content\/uploads\/2025\/04\/3004-1.webp\" \/>\n\t<meta property=\"og:image:width\" content=\"1080\" \/>\n\t<meta property=\"og:image:height\" content=\"608\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/png\" \/>\n<meta name=\"author\" content=\"Fineline Cube\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:description\" content=\"Navigate the complexities of China\u2019s pharmaceutical industry with precision and clarity. FLCUBE delivers reliable data, news, and intelligence to broaden your horizons and sharpen your decision-making. Stay informed, stay ahead with FLCUBE.COM\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Fineline Cube\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"1 minute\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=32732#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=32732\"},\"author\":{\"name\":\"Fineline Cube\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/person\\\/19ad11870d326204db8524d3c3c5e66a\"},\"headline\":\"Fosun Pharma&#8217;s Henlius Strikes Deal with Sandoz for Global Rights to HLX13 Biosimilar\",\"datePublished\":\"2025-04-30T03:48:25+00:00\",\"dateModified\":\"2025-04-30T03:48:26+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=32732\"},\"wordCount\":178,\"commentCount\":0,\"publisher\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"},\"image\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=32732#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2025\\\/04\\\/3004-1.webp\",\"keywords\":[\"BMS\",\"Bristol-Myers Squibb\",\"Cancer\",\"Fosun Pharmaceutical\",\"Henlius Biotech\",\"HKG: 2196\",\"HKG: 2696\",\"NYSE: BMY\",\"Sandoz\",\"SHA: 600196\",\"SWX: SDZ\"],\"articleSection\":[\"Company\",\"Deals\"],\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"CommentAction\",\"name\":\"Comment\",\"target\":[\"https:\\\/\\\/flcube.com\\\/?p=32732#respond\"]}],\"copyrightYear\":\"2025\",\"copyrightHolder\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"}},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=32732\",\"url\":\"https:\\\/\\\/flcube.com\\\/?p=32732\",\"name\":\"Fosun Pharma's Henlius Strikes Deal with Sandoz for Global Rights to HLX13 Biosimilar - Insight, China&#039;s Pharmaceutical Industry\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=32732#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=32732#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2025\\\/04\\\/3004-1.webp\",\"datePublished\":\"2025-04-30T03:48:25+00:00\",\"dateModified\":\"2025-04-30T03:48:26+00:00\",\"description\":\"China-based Shanghai Fosun Pharmaceutical (Group) Co., Ltd (SHA: 600196, HKG: 2196) announced that its subsidiary Shanghai Henlius Biotech Inc. (HKG: 2696) has entered into a licensing agreement with Sandoz (SWX: SDZ). The deal grants the Swiss pharmaceutical company development, manufacturing, and commercialization rights for HLX13\u2014a biosimilar of Bristol-Myers Squibb (BMS, NYSE: BMY)'s Yervoy (ipilimumab)\u2014in Australia, Canada, Europe, Japan, and the US.\",\"breadcrumb\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=32732#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/flcube.com\\\/?p=32732\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=32732#primaryimage\",\"url\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2025\\\/04\\\/3004-1.webp\",\"contentUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2025\\\/04\\\/3004-1.webp\",\"width\":1080,\"height\":608,\"caption\":\"Fosun Pharma's Henlius Strikes Deal with Sandoz for Global Rights to HLX13 Biosimilar\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=32732#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/flcube.com\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Fosun Pharma&#8217;s Henlius Strikes Deal with Sandoz for Global Rights to HLX13 Biosimilar\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#website\",\"url\":\"https:\\\/\\\/flcube.com\\\/\",\"name\":\"Insight, China's Pharmaceutical Industry\",\"description\":\"Fineline Insights, Pharma Clarity\",\"publisher\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/flcube.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Organization\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\",\"name\":\"Fineline Infomation and Technology\",\"alternateName\":\"Fineline Info & Tech\",\"url\":\"https:\\\/\\\/flcube.com\\\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/logo\\\/image\\\/\",\"url\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2024\\\/11\\\/Fineline-info-tech-scaled.jpg\",\"contentUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2024\\\/11\\\/Fineline-info-tech-scaled.jpg\",\"width\":2560,\"height\":1894,\"caption\":\"Fineline Infomation and Technology\"},\"image\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/logo\\\/image\\\/\"},\"sameAs\":[\"https:\\\/\\\/www.facebook.com\\\/profile.php?id=61566606313834\"]},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/person\\\/19ad11870d326204db8524d3c3c5e66a\",\"name\":\"Fineline Cube\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"caption\":\"Fineline Cube\"},\"sameAs\":[\"https:\\\/\\\/flcube.com\"],\"url\":\"https:\\\/\\\/flcube.com\\\/?author=1\"}]}<\/script>\n<!-- \/ Yoast SEO Premium plugin. -->","yoast_head_json":{"title":"Fosun Pharma's Henlius Strikes Deal with Sandoz for Global Rights to HLX13 Biosimilar - Insight, China&#039;s Pharmaceutical Industry","description":"China-based Shanghai Fosun Pharmaceutical (Group) Co., Ltd (SHA: 600196, HKG: 2196) announced that its subsidiary Shanghai Henlius Biotech Inc. (HKG: 2696) has entered into a licensing agreement with Sandoz (SWX: SDZ). The deal grants the Swiss pharmaceutical company development, manufacturing, and commercialization rights for HLX13\u2014a biosimilar of Bristol-Myers Squibb (BMS, NYSE: BMY)'s Yervoy (ipilimumab)\u2014in Australia, Canada, Europe, Japan, and the US.","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/flcube.com\/?p=32732","og_locale":"en_US","og_type":"article","og_title":"Fosun Pharma's Henlius Strikes Deal with Sandoz for Global Rights to HLX13 Biosimilar","og_description":"China-based Shanghai Fosun Pharmaceutical (Group) Co., Ltd (SHA: 600196, HKG: 2196) announced that its subsidiary Shanghai Henlius Biotech Inc. (HKG: 2696) has entered into a licensing agreement with Sandoz (SWX: SDZ). The deal grants the Swiss pharmaceutical company development, manufacturing, and commercialization rights for HLX13\u2014a biosimilar of Bristol-Myers Squibb (BMS, NYSE: BMY)'s Yervoy (ipilimumab)\u2014in Australia, Canada, Europe, Japan, and the US.","og_url":"https:\/\/flcube.com\/?p=32732","og_site_name":"Insight, China&#039;s Pharmaceutical Industry","article_publisher":"https:\/\/www.facebook.com\/profile.php?id=61566606313834","article_published_time":"2025-04-30T03:48:25+00:00","article_modified_time":"2025-04-30T03:48:26+00:00","og_image":[{"width":1080,"height":608,"url":"https:\/\/flcube.com\/wp-content\/uploads\/2025\/04\/3004-1.webp","type":"image\/png"}],"author":"Fineline Cube","twitter_card":"summary_large_image","twitter_description":"Navigate the complexities of China\u2019s pharmaceutical industry with precision and clarity. FLCUBE delivers reliable data, news, and intelligence to broaden your horizons and sharpen your decision-making. Stay informed, stay ahead with FLCUBE.COM","twitter_misc":{"Written by":"Fineline Cube","Est. reading time":"1 minute"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/flcube.com\/?p=32732#article","isPartOf":{"@id":"https:\/\/flcube.com\/?p=32732"},"author":{"name":"Fineline Cube","@id":"https:\/\/flcube.com\/#\/schema\/person\/19ad11870d326204db8524d3c3c5e66a"},"headline":"Fosun Pharma&#8217;s Henlius Strikes Deal with Sandoz for Global Rights to HLX13 Biosimilar","datePublished":"2025-04-30T03:48:25+00:00","dateModified":"2025-04-30T03:48:26+00:00","mainEntityOfPage":{"@id":"https:\/\/flcube.com\/?p=32732"},"wordCount":178,"commentCount":0,"publisher":{"@id":"https:\/\/flcube.com\/#organization"},"image":{"@id":"https:\/\/flcube.com\/?p=32732#primaryimage"},"thumbnailUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2025\/04\/3004-1.webp","keywords":["BMS","Bristol-Myers Squibb","Cancer","Fosun Pharmaceutical","Henlius Biotech","HKG: 2196","HKG: 2696","NYSE: BMY","Sandoz","SHA: 600196","SWX: SDZ"],"articleSection":["Company","Deals"],"inLanguage":"en-US","potentialAction":[{"@type":"CommentAction","name":"Comment","target":["https:\/\/flcube.com\/?p=32732#respond"]}],"copyrightYear":"2025","copyrightHolder":{"@id":"https:\/\/flcube.com\/#organization"}},{"@type":"WebPage","@id":"https:\/\/flcube.com\/?p=32732","url":"https:\/\/flcube.com\/?p=32732","name":"Fosun Pharma's Henlius Strikes Deal with Sandoz for Global Rights to HLX13 Biosimilar - Insight, China&#039;s Pharmaceutical Industry","isPartOf":{"@id":"https:\/\/flcube.com\/#website"},"primaryImageOfPage":{"@id":"https:\/\/flcube.com\/?p=32732#primaryimage"},"image":{"@id":"https:\/\/flcube.com\/?p=32732#primaryimage"},"thumbnailUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2025\/04\/3004-1.webp","datePublished":"2025-04-30T03:48:25+00:00","dateModified":"2025-04-30T03:48:26+00:00","description":"China-based Shanghai Fosun Pharmaceutical (Group) Co., Ltd (SHA: 600196, HKG: 2196) announced that its subsidiary Shanghai Henlius Biotech Inc. (HKG: 2696) has entered into a licensing agreement with Sandoz (SWX: SDZ). The deal grants the Swiss pharmaceutical company development, manufacturing, and commercialization rights for HLX13\u2014a biosimilar of Bristol-Myers Squibb (BMS, NYSE: BMY)'s Yervoy (ipilimumab)\u2014in Australia, Canada, Europe, Japan, and the US.","breadcrumb":{"@id":"https:\/\/flcube.com\/?p=32732#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/flcube.com\/?p=32732"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/flcube.com\/?p=32732#primaryimage","url":"https:\/\/flcube.com\/wp-content\/uploads\/2025\/04\/3004-1.webp","contentUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2025\/04\/3004-1.webp","width":1080,"height":608,"caption":"Fosun Pharma's Henlius Strikes Deal with Sandoz for Global Rights to HLX13 Biosimilar"},{"@type":"BreadcrumbList","@id":"https:\/\/flcube.com\/?p=32732#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/flcube.com\/"},{"@type":"ListItem","position":2,"name":"Fosun Pharma&#8217;s Henlius Strikes Deal with Sandoz for Global Rights to HLX13 Biosimilar"}]},{"@type":"WebSite","@id":"https:\/\/flcube.com\/#website","url":"https:\/\/flcube.com\/","name":"Insight, China's Pharmaceutical Industry","description":"Fineline Insights, Pharma Clarity","publisher":{"@id":"https:\/\/flcube.com\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/flcube.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Organization","@id":"https:\/\/flcube.com\/#organization","name":"Fineline Infomation and Technology","alternateName":"Fineline Info & Tech","url":"https:\/\/flcube.com\/","logo":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/flcube.com\/#\/schema\/logo\/image\/","url":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg","contentUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg","width":2560,"height":1894,"caption":"Fineline Infomation and Technology"},"image":{"@id":"https:\/\/flcube.com\/#\/schema\/logo\/image\/"},"sameAs":["https:\/\/www.facebook.com\/profile.php?id=61566606313834"]},{"@type":"Person","@id":"https:\/\/flcube.com\/#\/schema\/person\/19ad11870d326204db8524d3c3c5e66a","name":"Fineline Cube","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","caption":"Fineline Cube"},"sameAs":["https:\/\/flcube.com"],"url":"https:\/\/flcube.com\/?author=1"}]}},"jetpack_publicize_connections":[],"jetpack_featured_media_url":"https:\/\/flcube.com\/wp-content\/uploads\/2025\/04\/3004-1.webp","jetpack_sharing_enabled":true,"_links":{"self":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/32732","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcomments&post=32732"}],"version-history":[{"count":1,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/32732\/revisions"}],"predecessor-version":[{"id":32737,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/32732\/revisions\/32737"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/media\/32736"}],"wp:attachment":[{"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fmedia&parent=32732"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcategories&post=32732"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Ftags&post=32732"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}